A visualisation of rare earth concentrates. Source: Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Brazilian Critical Minerals (ASX:BCM) has updated the market on its Brazilian Ema Project, reporting the company achieved REE recoveries up to 87%.

The company highlighted neodymium (Nd) and praseodymium (Pr) – the two best known high-value rare earths – as well as dysprosium and terbium, more obscure metals.

One 13m intersection part of recovery testing saw recoveries of 71% Nd and 62% Pr.

The company says it achieved this using a “weak ammonium sulphate leaching solution” over leach times of only 30 minutes.

Those tests confirm “rare earths are present in ionic form and leachable at low operating cost,” BCM reported on Wednesday.

BCM NEC Jeremy Robinson outlined where the company’s now looking.

“Our immediate focus is to complete the maiden Ema Mineral Resource Estimate with all the data having been handed over to the consultants for processing,” Robinson said.

“At the same time, [we’re] proceeding with further metallurgical optimisation test-work at ANSTO which will commence shortly, with samples having already been delivered.”

In the background of BCM’s Wednesday update, a maiden JORC MRE is being prepared for Ema by geotechs on-site.

Drillers will be returning on-site to re-drill certain assets which the company believes contain higher grade REE mineralisation deeper underground.

BCM shares last traded at 2.6c.

BCM by the numbers
More From The Market Online
Market Close Graphic

ASX Market Close: Another reversal as just-green Oz markets ignore US dive | Jan 3, 2024

The Aussie bourse has defied morning expectations for the second time in as many days, closing out all but flat with a 0.
A Red Sky Energy rig out in the ocean.

Red Sky Energy bleeds more than 18% after ‘landmark’ Angola block entry

Red Sky Energy was ready to pop champagne after being awarded 35% in a "transformative" Angola…
A patient being dosed with Imugene Limited testing materials.

First Aussie doses bring Imugene major step closer to ‘quicker, cheaper’ non-Hodgkin’s lymphoma care

Imugene Limited (ASX:IMU) has hit its first important milestone in 2025, dosing its first Australian patient with its allogenic
A market trading board with ASX marked on the side.

‘Shine a light’: ASX to get more aggressive on companies ‘not up to scratch’ on disclosures

The Australian Securities Exchange (ASX:ASX) will be taking poor disclosure from market-listed companies far more seriously through this next